Nanjing Vazyme Biotech Co (SHSE:688105) Common Stock: ¥398 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688105 Nanjing Vazyme Biotech Co Ltd SHSE:688105
68 GF Score
Price ¥23.22
GF Value ¥17.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nanjing Vazyme Biotech Co Common Stock?

Nanjing Vazyme Biotech Co SHSE:688105 +18.59% 68 Common Stock is ¥398 Mil as of Mar. 2026. GuruFocus rates SHSE:688105 with a GF Score™ of 68/100 and a GF Value™ of ¥17.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Nanjing Vazyme Biotech Co's quarterly common stock stayed the same from Sep. 2025 (¥398 Mil) to Dec. 2025 (¥398 Mil) and stayed the same from Dec. 2025 (¥398 Mil) to Mar. 2026 (¥398 Mil).

Nanjing Vazyme Biotech Co's annual common stock increased from Dec. 2023 (¥400 Mil) to Dec. 2024 (¥402 Mil) but then declined from Dec. 2024 (¥402 Mil) to Dec. 2025 (¥398 Mil).

Nanjing Vazyme Biotech Co Common Stock Historical Data

* Premium members only.

The historical data trend for Nanjing Vazyme Biotech Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Vazyme Biotech Co Common Stock Chart

Nanjing Vazyme Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only 400.01 400.01 400.01 402.13 397.74

Nanjing Vazyme Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 397.74 397.74 397.74 397.74 397.74
SHSE:688105
68GF Score
Nanjing Vazyme Biotech Co Ltd SHSE:688105
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Vazyme Biotech Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of ¥398 Mil mean?
Nanjing Vazyme Biotech Co (SHSE:688105) has a Common Stock of ¥398 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Nanjing Vazyme Biotech Co and its competitors.
Is Nanjing Vazyme Biotech Co's Common Stock too high?
Nanjing Vazyme Biotech Co's current Common Stock is ¥398 Mil. Overall, Nanjing Vazyme Biotech Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vazyme Biotech Co's Common Stock compare to VRTX and REGN?
Nanjing Vazyme Biotech Co's Common Stock of ¥398 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Nanjing Vazyme Biotech Co and its competitors. Nanjing Vazyme Biotech Co's current Common Stock is ¥398 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vazyme Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co (SHSE:688105) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.03, compared to a current price of ¥23.22 — trading 36.3% above its estimated fair value. The current Common Stock is ¥398 Mil. Nanjing Vazyme Biotech Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Nanjing Vazyme Biotech Co (SHSE:688105), the current Common Stock is ¥398 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing Vazyme Biotech Co (SHSE:688105) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co stock appears to be overvalued. The current stock price of ¥23.22 is trading 36.3% above its estimated GF Value™ of ¥17.03. GuruFocus considers Nanjing Vazyme Biotech Co to be Significantly Overvalued.

Key valuation signals for SHSE:688105:

  • Common Stock: ¥398 Mil
  • GF Value™: ¥17.03 vs. price of ¥23.22 (36.3% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanjing Vazyme Biotech Co Business Description

Address Kechuang Road, Floor 1-6, East Section, Building C1-2, Hongfeng Science and Technology Park, Jiangsu, Economic and Technological Development Zone, Nanjing, CHN, 210000
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
68GF Score

Get the complete analysis for SHSE:688105

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥23.22
Price
¥17.03
GF Value